CorMedix Inc at RBC Capital Markets Global Healthcare Conference Transcript
Welcome to the 2023 RBC Global Healthcare Conference. I'm Rahul Sood, managing director in the healthcare investment banking group. And I'm joined on the stage today by Joe Todisco, the CEO of CorMedix. Joe, thanks for joining.
Thank you.
Questions & Answers
Okay. So for those of us who aren't familiar with the CorMedix story, can you please provide us with a brief intro of the company and the lead asset, DefenCath, specifically, how DefenCath differentiated from the current products and procedures in place to protect against catheter-related bloodstream infections?
All right. Sure. Thanks. Well, thanks, those of you that are in here, for joining.
So CorMedix is a pre-commercial stage biotech company. And our lead product, DefenCath, the NDA was just resubmitted to FDA this past Monday. So the product
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |